A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Desilets A, Pfister DG, Stein S, Wong W, et al. Oral Oncol 2024;154:106861.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Desilets A, Pfister DG, Stein S, Wong W, et al. A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer. Oral Oncol 2024;154:106861.
PMID: 38795600